Odimma Therapeutics, a biotechnology company specialized in personalized cancer immunotherapy announces a seed fundraising of €2 million in order to secure the preparation on its First-in-Man clinical
Touchlight and Odimma have entered into an agreement to develop and supply clinical material for Odimma's neoantigen program Touchlight, a biotechnology company pioneering enzymatic DNA production